SCHEMBL1153785

SCHEMBL1153785

COc1ccccc1C(O)(c1ccccc1OC)[C@@H](C)NC(=O)C1(C(=O)N[C@H](C)C(O)(c2ccccc2OC)c2ccccc2OC)CC1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.41
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 1/20 0.37
ATM Q13315 1/20 0.37
PKM P14618 1/20 0.36
RBP4 P02753 1/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.35
MTNR1A P48039 1/20 0.35
MTNR1B P49286 1/20 0.35
KCNK3 O14649 1/20 0.34
KCNK9 Q9NPC2 1/20 0.34
EGFR P00533 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1153935 0.95 L3MBTL1 (0.43) GAAKMT2AMEN1L3MBTL1ALDH1A1
SCHEMBL1154023 0.95 L3MBTL1 (0.41) GAAKMT2AMEN1L3MBTL1ALDH1A1
SCHEMBL1153096 0.94 L3MBTL1 (0.43) GAAKMT2AMEN1L3MBTL1ALDH1A1
SCHEMBL1152091 0.87 GAA (0.40) GAAKMT2AMEN1L3MBTL1ALDH1A1
SCHEMBL1153753 0.86 GAA (0.40) GAAKMT2AMEN1L3MBTL1ALDH1A1
SCHEMBL1153168 0.85 ANPEP (0.41) GAAKMT2AMEN1L3MBTL1ALDH1A1
SCHEMBL1153344 0.84 ALDH1A1 (0.40) GAAKMT2AMEN1L3MBTL1ALDH1A1
SCHEMBL4350908 0.83 GAA (0.47) GAAKMT2AMEN1L3MBTL1ALDH1A1
SCHEMBL1153971 0.83 L3MBTL1 (0.39) GAAKMT2AMEN1L3MBTL1ALDH1A1
SCHEMBL1152660 0.83 L3MBTL1 (0.42) GAAKMT2AMEN1L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943799-B2 Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-17 US disclosed
US-20110046415-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-02-24 US disclosed
US-7842839-B2 Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-11-30 US disclosed
US-20070112201-A1 Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-05-17 US disclosed
EP-1698617-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENE BISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF Sumitomo Chemical Company, Limited (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112201-A1 Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof CYP3A7, GRK7, CYP2A7 GAA 3726/4885KMT2A 3425/4885MEN1 3372/4885
US-20110046415-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF CYP3A7, GRK7, CYP2A7 GAA 3726/4885KMT2A 3425/4885MEN1 3372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.